Benzinga·2026-01-20 14:02分组1 - Super Micro Computer, Inc. is recommended to be sold by Jim Cramer, with Goldman Sachs analyst Katherine Murphy assigning a Sell rating and a price target of $26 [1] - Alkermes plc is not recommended by Cramer [1] - Alixorexton received Breakthrough Therapy designation from the FDA for Narcolepsy Type 1 treatment [2] 分组2 - UiPath, Inc. has an upside potential according to Cramer, with Barclays analyst Raimo Lenschow maintaining an Equal-Weight rating and raising the price target from $16 to $18 [2] - Huntington Bancshares Incorporated is viewed positively by Cramer, who stated it is "terrific," and shareholders approved a merger with Cadence Bank [2] - Smith & Nephew plc is advised to be sold, with Canaccord Genuity analyst Caitlin Cronin lowering the price target from $36 to $34 [3] 分组3 - Medline Inc. is recommended as a buy by Cramer, supported by multiple analysts initiating coverage with bullish ratings [3] - STMicroelectronics N.V. is also recommended for purchase, described as "cheap" and "good" by Cramer [3] - STMicroelectronics is set to release its fourth quarter and full year 2025 earnings on January 29 [4] 分组4 - Super Micro Computer shares increased by 11.1% to $32.66, while Alkermes shares rose by 1.3% to $31.63 [7] - Huntington Bancshares shares gained 0.4% to $18.02, and UiPath shares fell by 3% to $14.34 [7] - Smith & Nephew shares decreased by 0.6% to $32.70, while Medline shares increased by 3.3% to $44.12, and STMicroelectronics shares gained 0.1% to $28.03 [7]